Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | May 01, 2026 | May 01, 2026 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | SVP & Chief Commercial Officer | June 25, 2026 | June 29, 2026 |
| DEXCOM INCDXCM · Entity 3114 | EVP Chief Commercial Officer | March 12, 2024 | March 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date May 01, 2026 · Filed May 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.82 · Expires 2036-05-01 | Direct | 48,800 |
Reported balance
After 2026-05-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-01 · Grant · Acquired 48,800 · Balance 48,800 F1: The options were granted pursuant to the Company's non-employee director compensation policy. F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted pursuant to the Company's non-employee director compensation policy.
F2: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date.
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 90,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 90,000 · Balance 90,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
F2: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.
DEXCOM INC
Report date March 12, 2024 · Filed March 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,641 |
Reported balance
After 2024-03-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-12 · Sale · Disposed 4,764 · Balance 66,641 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2: Included in this number are 60,067 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 34,014 of which were granted on March 8, 2023 and shall vest through March 8, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2: Included in this number are 60,067 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 34,014 of which were granted on March 8, 2023 and shall vest through March 8, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:21 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantIncentive Stock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001960596-26-000004 · form4-06292026_080655.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on June 25, 2027 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| May 01, 2026 Filed May 1, 2026 20:23 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $2.82 | $0.00 |
DisclosureSEC source: 0001960596-26-000002 · form4-05012026_080512.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2036-05-01 F1 · security: The options were granted pursuant to the Company's non-employee director compensation policy. F2 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| November 10, 2025 Filed Nov 12, 2025 21:12 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantISO (right to buy) · Derivative | 100,000 | $0.00 Strike: $22.67 | $0.00 |
DisclosureSEC source: 0001960596-25-000008 · form4-11122025_091122.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2035-11-10 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: 25% vest on November 10, 2026 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. Read SEC document |
| September 25, 2025 Filed Sep 29, 2025 20:19 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 48,800 | $0.00 Strike: $3.92 | $0.00 |
DisclosureSEC source: 0001104659-25-094497 · tm2527377-7_4seq1.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,800 Underlying: Common Stock, par value $0.0001 · 48,800 shares Expires 2035-09-25 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following September 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 23:47 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 69,800 | $0.00 Strike: $6.11 | $0.00 |
DisclosureSEC source: 0001104659-25-017580 · tm257585-4_4seq1.xml · derivative · entry 1 Lawver Teri L · CIK 0001960596 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,800 Underlying: Common Stock, par value $0.0001 · 69,800 shares Expires 2035-02-24 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable in 36 substantially equal monthly installments following February 24, 2025 subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:39 UTC | DEXCOM INC DXCM · Entity 3114 | SaleCommon Stock | 4,764 | $134.41 | $640,332.57 |
DisclosureSEC source: 0001093557-24-000050 · edgardoc.xml · nonDerivative · entry 1 Lawver Teri L · CIK 0001960596 · EVP Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,641 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · balance_after: Included in this number are 60,067 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 34,014 of which were granted on March 8, 2023 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 22:31 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 26,053 | $0.00 | $0.00 |
DisclosureSEC source: 0001093557-24-000036 · edgardoc.xml · nonDerivative · entry 1 Lawver Teri L · CIK 0001960596 · EVP Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,405 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 60,067 unvested restricted stock units, 26,053 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 34,014 of which were granted on March 8, 2023 and shall vest through March 8, 2027. Read SEC document |
| March 08, 2023 Filed Mar 10, 2023 21:00 UTC | DEXCOM INC DXCM · Entity 3114 | GrantCommon Stock | 45,352 | $0.00 | $45.35 |
DisclosureSEC source: 0001093557-23-000055 · edgardoc.xml · nonDerivative · entry 1 Lawver Teri L · CIK 0001960596 · EVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,352 F1 · shares: Represents a grant of restricted stock units that are exempt from Section 16 b-3 and are subject to vesting in four equal annual installments from the date of grant. Share units represent a contingent right to receive one share of DexCom, Inc. Common Stock. F2 · balance_after: Included in this number are 45,352 unvested restricted stock units, 45,352 of which were granted on March 8, 2023 and shall vest through March 8, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.